UNIQURE NV (QURE) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:QURE • NL0010696654

24.71 USD
-1.34 (-5.14%)
At close: Feb 10, 2026
24.614 USD
-0.1 (-0.39%)
Pre-Market: 2/11/2026, 8:00:02 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, QURE scores 3 out of 10 in our fundamental rating. QURE was compared to 523 industry peers in the Biotechnology industry. QURE may be in some trouble as it scores bad on both profitability and health. QURE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year QURE has reported negative net income.
  • In the past year QURE has reported a negative cash flow from operations.
  • QURE had negative earnings in 4 of the past 5 years.
  • QURE had negative operating cash flow in 4 of the past 5 years.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

  • QURE has a better Return On Assets (-26.47%) than 69.79% of its industry peers.
  • With a Return On Equity value of -102.80%, QURE perfoms like the industry average, outperforming 45.70% of the companies in the same industry.
Industry RankSector Rank
ROA -26.47%
ROE -102.8%
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • Looking at the Gross Margin, with a value of 88.13%, QURE belongs to the top of the industry, outperforming 90.25% of the companies in the same industry.
  • QURE's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, QURE has more shares outstanding
  • Compared to 5 years ago, QURE has more shares outstanding
  • The debt/assets ratio for QURE is higher compared to a year ago.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -0.45, we must say that QURE is in the distress zone and has some risk of bankruptcy.
  • QURE's Altman-Z score of -0.45 is in line compared to the rest of the industry. QURE outperforms 58.89% of its industry peers.
  • QURE has a Debt/Equity ratio of 2.26. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of QURE (2.26) is worse than 78.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Altman-Z -0.45
ROIC/WACCN/A
WACC6.44%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • QURE has a Current Ratio of 7.12. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.12, QURE is doing good in the industry, outperforming 70.55% of the companies in the same industry.
  • QURE has a Quick Ratio of 7.12. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
  • QURE's Quick ratio of 7.12 is fine compared to the rest of the industry. QURE outperforms 71.13% of its industry peers.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 7.12
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
  • Looking at the last year, QURE shows a very negative growth in Revenue. The Revenue has decreased by -44.90% in the last year.
  • Measured over the past years, QURE shows a very strong growth in Revenue. The Revenue has been growing by 30.01% on average per year.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.65%
Revenue 1Y (TTM)-44.9%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%61.83%

3.2 Future

  • QURE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.19% yearly.
  • The Revenue is expected to grow by 72.19% on average over the next years. This is a very strong growth
EPS Next Y19.53%
EPS Next 2Y14.18%
EPS Next 3Y14.73%
EPS Next 5Y21.19%
Revenue Next Year-60.9%
Revenue Next 2Y-2.54%
Revenue Next 3Y63.14%
Revenue Next 5Y72.19%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • QURE's earnings are expected to grow with 14.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.18%
EPS Next 3Y14.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for QURE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNIQURE NV

NASDAQ:QURE (2/10/2026, 8:00:02 PM)

Premarket: 24.614 -0.1 (-0.39%)

24.71

-1.34 (-5.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-02
Inst Owners91.11%
Inst Owner Change4.1%
Ins Owners1.48%
Ins Owner Change-0.35%
Market Cap1.54B
Revenue(TTM)15.75M
Net Income(TTM)-235.15M
Analysts83
Price Target51.51 (108.46%)
Short Float %19.8%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.02%
Min EPS beat(2)-50.39%
Max EPS beat(2)24.35%
EPS beat(4)2
Avg EPS beat(4)-36.4%
Min EPS beat(4)-139.62%
Max EPS beat(4)24.35%
EPS beat(8)4
Avg EPS beat(8)-16.52%
EPS beat(12)5
Avg EPS beat(12)-30.89%
EPS beat(16)8
Avg EPS beat(16)-14%
Revenue beat(2)0
Avg Revenue beat(2)-20.37%
Min Revenue beat(2)-30.8%
Max Revenue beat(2)-9.94%
Revenue beat(4)0
Avg Revenue beat(4)-46.9%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)-9.94%
Revenue beat(8)3
Avg Revenue beat(8)-18.19%
Revenue beat(12)4
Avg Revenue beat(12)-5.3%
Revenue beat(16)5
Avg Revenue beat(16)5.32%
PT rev (1m)-5.04%
PT rev (3m)-30.65%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-1.51%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)-15.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.78%
Revenue NY rev (1m)-5.85%
Revenue NY rev (3m)-14.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 97.72
P/FCF N/A
P/OCF N/A
P/B 6.73
P/tB 11.91
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.25
BVpS3.67
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.47%
ROE -102.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.13%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.23%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 7.12
Altman-Z -0.45
F-Score5
WACC6.44%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.65%
EPS Next Y19.53%
EPS Next 2Y14.18%
EPS Next 3Y14.73%
EPS Next 5Y21.19%
Revenue 1Y (TTM)-44.9%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%61.83%
Revenue Next Year-60.9%
Revenue Next 2Y-2.54%
Revenue Next 3Y63.14%
Revenue Next 5Y72.19%
EBIT growth 1Y7.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.83%
EBIT Next 3Y9.61%
EBIT Next 5Y24.88%
FCF growth 1Y4.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.42%
OCF growth 3YN/A
OCF growth 5YN/A

UNIQURE NV / QURE FAQ

Can you provide the ChartMill fundamental rating for UNIQURE NV?

ChartMill assigns a fundamental rating of 3 / 10 to QURE.


What is the valuation status for QURE stock?

ChartMill assigns a valuation rating of 0 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.


What is the profitability of QURE stock?

UNIQURE NV (QURE) has a profitability rating of 2 / 10.


How financially healthy is UNIQURE NV?

The financial health rating of UNIQURE NV (QURE) is 3 / 10.


What is the expected EPS growth for UNIQURE NV (QURE) stock?

The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to grow by 19.53% in the next year.